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ConsensusAbstract Background: Synchronous oligometastatic disease (sOM) has been described as a
distinct disease entity; however, there is no consensus on OM definition (OM-d) in non
esmall-cell lung cancer (NSCLC). A consensus group was formed aiming to agree on a com-
mon OM-d that could be used in future clinical trials. A European survey was circulated to
generate questions and input for the consensus group meeting.
Methods: A European Organisation for Research and Treatment of Cancer Lung Cancer
Group (LCG)/sOM-d consensus group survey was distributed to LCG, sOM-d consensus
group, and several European thoracic oncology societies’ members.
Results: 444 responses were analysed (radiation oncologist: 55% [n Z 242], pulmonologist:
15% [n Z 66], medical oncologist: 14% [n Z 64]). 361 physicians (81%) aimed to cure sOM
NSCLC patients and 82% (nZ 362) included the possibility of radical intent treatment in their
sOM-d. The maximum number of metastases considered in sOM-d varied: 12% replied 1
metastasis, 42%  3, and 17%  5 metastases. 79% (n Z 353) stated that number of organs
involved was important for sOM-d, and most (80%, n Z 355) considered that only 3
involved organs (excluding primary) should be included. 317 (72%) included mediastinal
lymph node involvement in the sOM-d and 22% (nZ 70/317) counted mediastinal lymph node
as a metastatic site. Most physicians completed sOM staging with brain magnetic resonance
imaging (91%, n Z 403) and positron emission tomography/computed tomography (98%,
n Z 437). Pathology proof of metastatic disease was a requirement to define sOM for 315
(71%) physicians. The preferred primary outcome for sOM clinical trials was overall survival
(73%, n Z 325).
Conclusion: Although consensual answers were obtained, several issues remain unresolved and
will require further research to agree on a sOM-d.
ª 2019 Elsevier Ltd. All rights reserved.1. Introduction
More than half of nonesmall-cell lung cancer (NSCLC)
patients present with stage IV disease at diagnosis, and up
to one-third of these patients have synchronous limited
metastatic (oligometastatic) disease [1e4]. Synchronous
oligometastatic disease (sOM) has been described as a
distinct disease entity. This state is characterized by
reduced metastatic potential with a limited number of
metastatic sites, which makes the local treatment of each
lesion possible [5]. Several single-arm phase 2 studies, and
multiple retrospectives series reported favourable out-
comes in highly selected sOM NSCLC patients who
received local radical treatments (LRT) [4,6e11]. Three
recent small (49e99 patients) randomized phase 2 studies
showed that progression-free survival (PFS) (and overall
survival [OS] in one study) [3] almost tripled with the
addition of LRT to systemic therapy compared with
systemic therapy alone in sOM NSCLC patients
responding to first-line systemic therapy [3,12,13].
There is, however, no consensus on what specific
criteria constitutes sOM NSCLC. Of note, inclusion
criteria for the previously cited studies were verydifferent. The number of metastatic lesions, number of
lesions per organ, type of organ specificity (e.g. inclusion
of intracranial lesions or mediastinal lymph nodes)
varied, resulting in difficultly comparing results of
different trials. The European Organisation for
Research and Treatment of Cancer Lung Cancer Group
(EORTC-LCG) initiated a consensus process. A
consensus group was formed aiming to agree on a
common NSCLC sOM definition (sOM-d) that could be
used in future clinical trials. A meeting to define the
statement was planned and, as a preparation for this
meeting, a systematic review [14], a survey, and real-life
sOM NSCLC cases were distributed. Results of this
preparatory work were used to identify areas of
consensus and areas for further discussion (Fig. S1). The
results of this survey are reported here.
2. Methods
2.1. Study design and population
An online (Google form) survey developed by the
EORTC-LCG was distributed on 14/12/2017 to all LCG
A. Levy et al. / European Journal of Cancer 122 (2019) 109e114 111and Radiation Oncology Group members of the
EORTC. National cancer societies in Europe (medical
oncology, pulmonology, radiation oncology) were also
asked to circulate the survey to their members. Re-
sponses were collected until 19th February 2018.
2.2. Description of the survey
The survey was strictly confidential and anonymous.
The questionnaire was divided into four sections: gen-
eral questions, sOM-d, sOM staging, and expected
benefit of local treatments. The questionnaire consisted
of 31 questions, 4 were “tick all boxes that apply” type
questions, and for all other questions, only one answer
could be selected. An initial survey draft was reviewed
by all EORTC LCG board members (n Z 14) and by a
panel of international experts in the field (n Z 12). The
final questionnaire was modified according to these ex-
perts’ comments and was designed to be completed in
approximately 10 min. A copy of the full survey is
available in the Supporting Information.
2.3. Statistical analysis
The chi-squared test was used for dichotomous variables
comparison (type of specialty: radiation oncologists vs.
others). A two-sided P-value <0.05 was considered sig-
nificant. All analyses were performed using software
SPSS version 19.Fig. 1. NSCLC synchronous oligometastatic definition.
Abbreviations: NSCLC, nonesmall-cell lung cancer.3. Results
3.1. General questions
A total of 444 responses were collected. Belgium
(n Z 62, 14%), Italy (n Z 55, 12%), UK (n Z 53, 12%),
Germany (n Z 47, 11%), and the Netherlands (n Z 44,
10%) contributed most (Table S1). Physicians specialties
were radiation oncologist: 55% (n Z 242), pulmonolo-
gist: 15% (n Z 66), medical oncologist: 14% (n Z 64),
surgeon: 7% (n Z 33), clinical oncologist: 7% (n Z 30),
and others: 2% (n Z 9). The main representing profes-
sion differed between countries with radiation oncolo-
gists constituting almost all responders in some
countries (Germany: n Z 46/47, 98%, Switzerland:
n Z 24/27, 93%). Most (78%, n Z 346) physicians had
>5 years of experience in treating NSCLC. Working
environment was university hospital (46%, n Z 206),
cancer centre (23%, n Z 103), general public hospital
(22%, n Z 98), and private centre (8%, n Z 37).3.2. Definition of synchronous oligometastatic NSCLC
A total of 81% (n Z 361) of physicians aimed to treat
sOM NSCLC with curative intent and the same per-
centage acknowledged that the possibility to treat the
patient with radical intent should be part of the sOM-
d (no difference according to specialty) (Fig. 1 and
Table S2). The majority (77%, nZ 344) did not consider
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maximum number of metastases allowed in the sOM-
d varied: 19%, 42%, 4%, and 17% replied 2, 3, 4, and
5 metastases, respectively. Some (16%) did not count
as long as radical treatment was possible. 80% (nZ 353)
stated that the number of organs involved was impor-
tant for the sOM-d, and most (80%, n Z 355) consid-
ered that only 3 involved organs (excluding the
primary tumour) should be considered sOM. 75%
(n Z 331) stated that the type of organs involved were
important for the sOM-d. In general, physicians
excluded organs that are not easily amenable to LRT
(e.g. 316/331 [95%] excluded meningeal and 269/331
[81%] excluded pericardial metastases, Fig. S2). Most
physicians (69%, n Z 309) acknowledged that it would
be helpful to divide sOM into oligometastatic risk
groups (Fig. S3). 384 (87%) considered pulmonary
metastasis (outside primary tumour, i.e. M1a) as a
metastatic site. 317 (72%) allowed mediastinal lymph
node involvement in the sOM-d but only 22% (n Z 70/
317) of them counted mediastinal lymph node as a
metastatic site. Of respondents favouring mediastinal
lymph node, 195/317 (62%) stated that there was no
specific issue regarding the mediastinal lymph node
volume/location as long as radical treatment was
possible. Almost half of the respondents (46%, n Z 204)
answered that the sOM-d should take into consideration
total tumour volume (i.e. volume of primary þ lymph
nodes þ metastases).3.3. Staging of synchronous oligometastatic NSCLC
Most physicians completed sOM staging with brain
magnetic resonance imaging (MRI) (91%, nZ 403), andFig. 2. Synchronous oligometastatic NSCLC staging.
Abbreviations: NSCLC, nonesmall-cell lung cancer; FDG, 18fluorodeoxyg18fluorodeoxyglucose (FDG) positron emission tomog-
raphy/computed tomography (PET-CT) (98%, n Z 437)
(Fig. 2 and Table S3). For mediastinal lymph node
staging, most respondents (76%, n Z 336/444) stated
that histology/cytology should be obtained: 85%
(n Z 285/336) in cases where PET-CT shows suspected
mediastinal lymph node or in case of a central primary
tumour and 15% (51/336) always performed mediastinal
staging. Investigations to obtain mediastinal lymph
node histology/cytology included EUS/EBUS (endo-
scopic ultrasound/endobronchial ultrasound) only (61%,
n Z 206/336) if representative material was obtained,
and mediastinoscopy directly or after negative EUS/
EBUS in 25% (n Z 84/336). Pathology proof of meta-
static disease was necessary in sOM for 315/444 (71%)
physicians. However, 131/315 (42%) stated that they
only obtained pathological proof when no lesion was
visible on CT/MRI (i.e. FDG-positive lesion on PET but
no tumour on CT or MRI). 256/369 (69%) always aimed
to obtain pathological proof (when safely possible) in
cases where only one metastasis is present, and 113/369
(21%) only when no lesion is identified on MRI/CT.3.4. Benefit of local treatments
The preferred primary outcome parameter in clinical
trials of sOM was OS (73%, n Z 325). Long-term OS
(45%, n Z 200), PFS (56%, n Z 249), and quality of life
(54%, n Z 238) were also selected (“tick all that apply”
question). 299/444 (65%) acknowledged that assessing
local control after stereotactic ablative body radio-
therapy (SABR) could be an issue (63% [188/299] radi-
ation oncologists vs. 37% [111/299] other specialties,
p < 0.001); however, PFS remained a reliable end-pointlucose; CT/MRI, computed tomography/magnetic-resonance imaging.
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ogists vs. 35% [96/274] other specialties, p < 0.001).4. Discussion
To the best of our knowledge, this is the first survey
collecting data on sOM NSCLC. Our results highlight
that for some items, consensus may easily be obtained.
For example, 81% of respondents stated that the aim of
OM treatment is cure, and that mandatory baseline
imaging should include PET-CT and brain MRI for
98% and 91% of respondents, respectively. This fits in
with recent recommendations by the EORTC to include
brain MRI and PET-CT in the workup of sOM NSCLC
patients [15]. In the recently published EORTC sys-
tematic review on sOM NSCLC, extended staging was
indeed mandated in most of the studies [14]. However,
several discussion points for the definition of sOM
remain, and these mainly include numbers of metastases
(it is suggested that SABR could also be of benefit in up
to 10 brain metastases in selected patients) [15], organ
type with metastasis (suggestion that patients with
limited pleural disease could benefit from LRT) [16], and
pathology requirements. This is also reflected in the
systematic review [14], the three randomized trials
[3,12,13], and case series [17], as no uniform definition of
sOM NSCLC could be retrieved. To standardize future
clinical trials evaluating the benefit of metastasis-
directed therapy in sOM, a common definition is
required.
The preferred primary outcome measure in our sur-
vey was OS, but OS was the primary outcome in only
one among three randomized phase II NSCLC OM
trials [3,12,13]. Furthermore, it was recognized by 63%
that evaluating local control after SABR could be
problematic, and only 62% stated that PFS was a reli-
able end-point after LRT.
Limitations of this survey include [18], first, the
absence of a response rate (respondents/total number of
physicians contacted) because the survey was circulated
by the national societies. Second, we did not subdivide
our questions according to mutational status or histol-
ogy. We also did not ask questions regarding the use of
biological markers or the type of response to first-line
systemic therapy as a selection criterion for LRT.
These two criteria could help the clinician to better select
patients more likely to benefit from LRT [19]. Third, we
only included questions on sOM and excluded meta-
chronous oligometastatic state or oligoprogressive dis-
ease, which hampers extrapolation to these two other
states. Finally, selection bias is possible in our study as
interested oncologists were more likely to respond to the
survey, but we did have a large number of respondents
and multiple represented disciplines. The respondents
represent a specific population. Most respondents came
from Western Europe and the networks used to send thequestionnaire generally targeted a specific population
(physician were members of scientific society or an or-
ganization that included patients in trials). It should,
however, be emphasized that NSCLC sOM patients
should preferably be treated or supervised by reference
centre proposing clinical trials.
5. Conclusion
Although consensual answers were obtained, several
issues remained unresolved and were discussed during a
sOM-d consensus group meeting. A consensus sOM-d is
proposed by the EORTC consensus group [20] to make
future clinical trials more homogeneous and to guide
clinicians in daily practice.
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